These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

369 related items for PubMed ID: 14966097

  • 1. Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide:
    Italian Group For Antiemetic Research.
    J Clin Oncol; 2004 Feb 15; 22(4):725-9. PubMed ID: 14966097
    [Abstract] [Full Text] [Related]

  • 2. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
    Van Belle S, Lichinitser MR, Navari RM, Garin AM, Decramer ML, Riviere A, Thant M, Brestan E, Bui B, Eldridge K, De Smet M, Michiels N, Reinhardt RR, Carides AD, Evans JK, Gertz BJ.
    Cancer; 2002 Jun 01; 94(11):3032-41. PubMed ID: 12115394
    [Abstract] [Full Text] [Related]

  • 3. Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
    Herrstedt J, Apornwirat W, Shaharyar A, Aziz Z, Roila F, Van Belle S, Russo MW, Levin J, Ranganathan S, Guckert M, Grunberg SM.
    J Clin Oncol; 2009 Nov 10; 27(32):5363-9. PubMed ID: 19805683
    [Abstract] [Full Text] [Related]

  • 4. Ondansetron and dexamethasone versus standard combination antiemetic therapy. A randomized trial for the prevention of acute and delayed emesis induced by cyclophosphamide-doxorubicin chemotherapy and maintenance of antiemetic effect at subsequent courses.
    Campora E, Giudici S, Merlini L, Rubagotti A, Rosso R.
    Am J Clin Oncol; 1994 Dec 10; 17(6):522-6. PubMed ID: 7977174
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Intravenous ondansetron plus intravenous dexamethasone with different ondansetron dosing schedules during multiple cycles of cisplatin-based chemotherapy.
    Chen PT, Liaw CC.
    Chang Gung Med J; 2008 Dec 10; 31(2):167-74. PubMed ID: 18567417
    [Abstract] [Full Text] [Related]

  • 10. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
    Chiou TJ, Tzeng WF, Wang WS, Yen CC, Fan FS, Liu JH, Chen PM.
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct 10; 63(10):729-36. PubMed ID: 11076429
    [Abstract] [Full Text] [Related]

  • 11. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
    Pradermdee P, Manusirivithaya S, Tangjitgamol S, Thavaramara T, Sukwattana P.
    J Med Assoc Thai; 2006 Oct 10; 89 Suppl 4():S29-36. PubMed ID: 17725140
    [Abstract] [Full Text] [Related]

  • 12. Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Herrington JD, Jaskiewicz AD, Song J.
    Cancer; 2008 May 01; 112(9):2080-7. PubMed ID: 18327813
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting.
    Voravud N, Sriuranpong V.
    J Med Assoc Thai; 2005 Dec 01; 88(12):1790-6. PubMed ID: 16518975
    [Abstract] [Full Text] [Related]

  • 16. The antiemetic efficacy of oral ondansetron plus intravenous dexamethasone in patients with gynecologic malignancies receiving carboplatin-based chemotherapy.
    Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J.
    Gynecol Oncol; 2000 Jul 01; 78(1):43-6. PubMed ID: 10873408
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R, Herrstedt J, Rapoport B, Carides AD, Guoguang-Ma J, Elmer M, Schmidt C, Evans JK, Horgan KJ.
    Eur J Cancer; 2004 Feb 01; 40(3):403-10. PubMed ID: 14746859
    [Abstract] [Full Text] [Related]

  • 19. Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: a randomized double-blind study.
    Roila F, Ruggeri B, Ballatori E, Del Favero A, Tonato M.
    J Clin Oncol; 2014 Jan 10; 32(2):101-6. PubMed ID: 24323030
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.